TherapeuticsMD, Inc.
No enriched coverage for $TXMD in the last 7 days.
No SEC Form 4 filings for $TXMD in the last 30 days.
TherapeuticsMD Inc. (TXMD) stock fell 1.49% on Thursday, closing at $1.99, despite an overall positive trading session for the broader market indices, including the NASDAQ Composite and the Dow Jones Industrial Average. The company's shares are currently 32.54% below their 52-week high of $2.95, which was reached on January 27th.
TherapeuticsMD (NASDAQ: TXMD) reported its first-quarter 2026 financial results, showing a net income from continuing operations of $103 thousand, a notable improvement from a loss in the previous year. The company saw an increase in license revenue, primarily from the Mayne License Agreement, and a decrease in total operating expenses. TherapeuticsMD continues to explore strategic alternatives, including potential acquisitions, mergers, or asset sales, as it transitions its business model to focus on pharmaceutical royalties.
TherapeuticsMD, Inc. (TXMD) has released its Quarterly Earnings Report (Form 10-Q) for the period ending March 31, 2026. The company, which transformed into a pharmaceutical royalty company in December 2022, reported a net income of $95 thousand for Q1 2026, a significant improvement from a net loss of $653 thousand in Q1 2025. This positive shift is primarily due to increased license revenue and reduced operating expenses, even as the company faces ongoing legal disputes and a "going concern" warning due to future liquidity needs.
